Work

Combined Cyclophosphamide, Fludarabine, Alemtuzumab, and Rituximab (CFAR), an Active Regimen for Heavily Treated Patients with CLL.

Year: 2006

Type: article

Study design: Clinical Trial

Source: Blood

DOI: 10.1182/blood.v108.11.31.31

Authors: William G. Wierda, Susan O’Brien, Stefan Faderl, Alessandra Ferrajoli, Farhad Ravandi-Kashani, Jorge Cortes, Francis Giles, Michael Andreeff, Charles Asa Koller, Susan Lerner, Hagop M. Kantarjian, Michael J. Keating

Institution: The University of Texas MD Anderson Cancer Center

Language: English

Topic: Chronic Lymphocytic Leukemia Research

Subfield: Genetics

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2565132879

FWCI: 4.011

Cites:

Cited by: 39

Related to: 10